Trudy Oliver, PhD, DCI member and professor of in the Duke Department of Pharmacology and Cancer Biology, received the Vicky Amidon Innovation in Lung Cancer Research Award from the Lung Cancer Initiative (LCI).
The award recognizes and provides research funding for innovative lung cancer projects that will improve the lives of those diagnosed with lung cancer in North Carolina. Since 2008, LCI has funded more than $4.2 million in lung cancer research through programs like the research fellowship grant, health disparities in lung cancer grant in partnership with the V Foundation for Cancer Research, Career Development Award, and the Vicky Amidon Innovation in Lung Cancer Research Award.
Oliver’s project will investigate why certain lung cancers become resistant to chemotherapy, specifically looking at the role of hillock-like cells in tumor progression.
“Dr. Oliver is an accomplished and highly respected investigator whose research program has made substantial contributions to the fields of tumor plasticity and preclinical modeling,” Lee Zou, PhD, chair of the Department of Pharmacology and Cancer Biology, said in a press release. “She is widely recognized for her leadership in dissecting the molecular mechanisms that underlie therapeutic resistance.”
